文献速递心律失常血脂与心血管预防

华法林控制指标与房颤结局的关联:ORBIT-AF注册研究

Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
PubMed 文献 · JAMA Cardiol · 2019-01-01

该多中心队列研究基于ORBIT-AF注册数据,纳入5545例(出血分析)和5635例(血栓分析)服用华法林的房颤患者,评估既往6个月华法林控制指标与随后6个月出血或血栓事件的关系。结果显示,治疗窗内时间、INR变异度和最大INR与出血风险独立相关,但无INR指标与卒中风险显著相关。

要点

  • 治疗窗内时间、INR变异度和最大INR与出血风险独立相关。
  • INR变异度加入临床风险模型仅轻微提高C统计量(0.68至0.69)。
  • 无INR控制指标与随后卒中风险显著相关。

核心结论

  • 三项既往华法林控制指标与出血风险相关,但仅略优于传统临床因素。
  • 本研究未发现任何INR控制指标与卒中风险显著相关。

研究设计与样本

  • 出血分析纳入5545例华法林治疗患者,血栓事件分析纳入5635例。

主要发现

  • 中位随访1.5年(IQR 1.0-2.5)期间发生339例大出血(6.1%)和51例卒中(0.9%)。
  • 调整临床出血风险后,治疗窗内时间(每1-SD增加≤55:aOR 1.16,95%CI 1.02-1.32)、INR变异度(aOR 1.32,95%CI 1.19-1.47)和最大INR(aOR 1.20,95%CI 1.10-1.31)仍与出血风险相关。
  • INR变异度加入临床风险模型使C统计量从0.68略升至0.69,净重分类改善指数为0.028(95%CI -0.029至0.067)。

关键数值与推荐

  • 治疗窗内时间定义为INR 2.0-3.0。
  • 分析的控制指标包括:治疗窗内时间、最近INR、INR低于2.0或高于3.0的插值时间百分比、INR方差、INR范围和INR在治疗范围内的百分比。

临床怎么用

  • 华法林治疗中可关注INR变异度和最大INR等指标,但其对出血风险的预测价值仅略优于传统临床因素。
  • INR控制指标未显示与卒中风险显著相关,卒中风险评估仍需依据其他临床因素。

局限性

  • 事后分析。
  • INR变异度加入临床模型对风险分层的改善有限(NRI 0.028,95%CI跨0)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Bleeding and thrombotic events (eg, stroke and systemic embolism) are common in patients with atrial fibrillation (AF) taking warfarin sodium despite a well-established therapeutic range. OBJECTIVE: To evaluate whether history of therapeutic warfarin control in patients with AF is independently associated with subsequent bleeding or thrombotic events. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter cohort study of 176 primary care, cardiology, and electrophysiology clinics in the United States, data were obtained during 51 830 visits among 10 137 patients with AF in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry; 5545 patients treated with warfarin were included in the bleeding analysis, and 5635 patients were included in the thrombotic event analysis. Patient follow-up was performed from June 29, 2010, to November 30, 2014. Data analysis was performed from August 4, 2016, to February 15, 2019. EXPOSURES: Multiple measures of warfarin control within the preceding 6 months were analyzed: time in therapeutic range of 2.0 to 3.0, most recent international normalized ratio (INR), percentage of time that a patient had interpolated INR values less than 2.0 or greater than 3.0, INR variance, INR range, and percentage of INR values in therapeutic range. MAIN OUTCOMES AND MEASURES: Association of INR measures, alone or in combination, with clinical factors and risk for thrombotic events and bleeding during the subsequent 6 months was assessed post hoc using logistic regression models. RESULTS: A total of 5545 patients (mean [SD] age, 74.5 [9.8] years; 3184 [57.4%] male) with AF were included in the major bleeding analysis and 5635 patients (mean [SD] age, 74.5 [9.8] years; 3236 [57.4%] male) in the thrombotic event analysis. During a median follow-up of 1.5 years (interquartile range, 1.0-2.5 years), there were 339 major bleeds (6.1%) and 51 strokes (0.9%). Multiple metrics of warfarin control were individually associated with subsequent bleeding. After adjustment for clinical bleeding risk, 3 measures-time in therapeutic range (per 1-SD increase ≤55: adjusted odds ratio [aOR], 1.16; 95% CI, 1.02-1.32), variation in INR values (aOR, 1.32; 95% CI, 1.19-1.47), and maximum INR (aOR, 1.20; 95% CI, 1.10-1.31)-remained associated with bleeding risk. Adding INR variance to a clinical risk model slightly increased the C statistic from 0.68 to 0.69 and had a net reclassification improvement index of 0.028 (95% CI, -0.029 to 0.067). No INR measures were associated with subsequent stroke risk. CONCLUSIONS AND RELEVANCE: Three metrics of prior warfarin control were associated with bleeding risk but only marginally more so than traditional clinical factors. This study did not identify any measures of INR control that were significantly associated with stroke risk.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Pokorney SD, Holmes DN, Thomas L, et al. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiol. 2019. PMID: 31268487. doi:10.1001/jamacardio.2019.1960

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。